Risk of Lymphoma in Patients with Asthma Treated with Dupilumab Compared with Other Biologic Agents: A Retrospective Cohort Study.
Dupilumab, widely used for asthma, does not appear to increase lymphoma risk compared to other modern biologics, providing reassurance about its long-term safety profile.
Dupilumab treatment in asthma patients was not associated with significantly elevated lymphoma risk compared to other biologic agents in a large retrospective cohort, providing important pharmacovigilance safety data for this widely-used IL-4/IL-13 antagonist. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective cohort study
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Chest
Why it surfaced
Important pharmacovigilance data for dupilumab-associated lymphoma risk, directly relevant to hematologic malignancy safety monitoring. Large retrospective cohort in Chest; dupilumab is prescribed to millions with atopic dermatitis and asthma. Safety reassurance has immediate clinical relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.